Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microbiota therapeutics for inflammatory bowel disease: the way forward
Lukas Bethlehem, María Manuela Estevinho, Ari Grinspan, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 476-486
Open Access | Times Cited: 21

Showing 21 citing articles:

Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Loris Riccardo Lopetuso, S Deleu, Pierluigi Puca, et al.
Inflammatory Bowel Diseases (2025)
Closed Access | Times Cited: 1
Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities
Iliyan D. Iliev, Ashwin N. Ananthakrishnan, Chun‐Jun Guo
Nature Reviews Microbiology (2025)
Closed Access | Times Cited: 1
Assessing live microbial therapeutic transmission
Jeremiah J. Faith
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Pharmacology of Intestinal Inflammation and Repair
Céline Deraison, Nathalie Vergnolle
The Annual Review of Pharmacology and Toxicology (2025) Vol. 65, Iss. 1, pp. 301-314
Closed Access
Comprehensive care of ulcerative colitis: new treatment strategies
Thanaboon Chaemsupaphan, Arteen Arzivian, Rupert W. Leong
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Inulin Hydrogel Loaded with Self-Assembled Nanoparticles of Curcumin and Glycyrrhizic Acid for Inflammatory Bowel Disease Treatment Via Anti-Inflammation, Antioxidation, and Microbiota Modulation
Jiaxin Wu, Leyan Wang, Lu Han, et al.
(2025)
Closed Access
Microbiota-derived metabolites in inflammatory bowel disease
Martina A. Guggeis, Danielle M M Harris, Lina Welz, et al.
Seminars in Immunopathology (2025) Vol. 47, Iss. 1
Open Access
Precision microbiota therapy for IBD: premise and promise
Manabu Nagayama, Lasha Gogokhia, Randy Longman
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access
Prediction and Prevention of Inflammatory Bowel Disease
Emily W. Lopes, Williams Turpin, Kenneth Croitoru, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 396-405.e1
Closed Access | Times Cited: 3
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs
Jose U. Scher, Renuka R. Nayak, José C. Clemente
Annals of the Rheumatic Diseases (2024) Vol. 84, Iss. 1, pp. 9-13
Closed Access | Times Cited: 3
The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia
Yuan Gao, Kaixuan Wang, Zupan Lin, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 2
Faecal phageome transplantation alleviates intermittent intestinal inflammation in IBD and the timing of transplantation matters: a preclinical proof-of-concept study in mice
Nengneng Li, Yue Li, Ziyu Huang, et al.
Gut (2024), pp. gutjnl-333598
Closed Access | Times Cited: 2
Leveraging human microbiomes for disease prediction and treatment
Henok Ayalew Tegegne, Tor Savidge
Trends in Pharmacological Sciences (2024)
Closed Access | Times Cited: 2
Combined effects of TiO2 nanoparticle and fipronil co-exposure on microbiota in mouse intestine
Canyang Wang, Yanxin Liu, Yayu He, et al.
Food and Chemical Toxicology (2024) Vol. 192, pp. 114931-114931
Closed Access | Times Cited: 1
Identification of novel indolinone derivatives as CTSC inhibitors to treat inflammatory bowel disease by modulating inflammatory factors
Xing Chen, Yan Lou, Feilong Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116914-116914
Closed Access | Times Cited: 1
The phageome of patients with ulcerative colitis treated with donor fecal microbiota reveals markers associated with disease remission
Marwan E. Majzoub, Sudarshan Paramsothy, Craig Haifer, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Unlocking the potential for microbiome‐based therapeutics to address the sustainable development goal of good health and wellbeing
Emily L. Gulliver, Sara K. Di Simone, Michelle Chonwerawong, et al.
Microbial Biotechnology (2024) Vol. 17, Iss. 11
Open Access | Times Cited: 1
wheel of microbiome rises, and it falls
Joanna Kołodziej, Paulina Krzemińska
Quality in Sport (2024) Vol. 15, pp. 53020-53020
Open Access
Ganjiang Huangqin Huanglian Renshen Decoction Protects Against Ulcerative Colitis by Modulating Inflammation, Oxidative Stress, and Gut Microbiota
Ce Zhou, Bo Peng, Mingxing Zhang, et al.
Phytomedicine (2024) Vol. 135, pp. 156172-156172
Open Access
The landscape of new therapeutic opportunities for IBD
Andrés Hurtado-Lorenzo, Jennifer L Swantek
Advances in pharmacology (2024), pp. 1-83
Closed Access
Gut Microbiota Causally Affects Ulcerative Colitis by Potential Mediation of Plasma Metabolites: a Mendelian Randomization Study
Shidong Zhao, Zheng Xiang, Weisong Shen, et al.
Research Square (Research Square) (2024)
Open Access
Huangqin Decoction Ameliorates Colitis by Modulating Gut Microbiota, Inhibiting Netosis, and Enhancing Intestinal Stem Cell Proliferation
Yuxia Pan, Gangfan Zong, Mingyuan Liu, et al.
(2024)
Closed Access
Page 1

Scroll to top